Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of KLU156 versus Coartem for uncomplicated Plasmodium falciparum malaria
PACTR202303470809477Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised trial of ganaplacide + lumefantrine-SDF in Malaria (2 arms), sponsored by Novartis. Primary endpoint: PCR-corrected adequate clinical and parasitological response at Day 29. Started Jul 2023; status: recruiting.
02
Drugs
ganaplacide + lumefantrine-SDF
03
Conditions
Malaria
Beyond the preview
Go deeper on PACTR202303470809477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202303470809477.